Bayer AG has discovered P2X purinoceptor 3 (P2RX3) antagonists reported to be useful for the treatment of overactive bladder, chronic cough, endometriosis, cancer, heart failure, irritable bowel syndrome with diarrhea, pain and sleep apnea, among others.
University of Chicago has described estrogen receptor (ER)-α antagonists reported to be useful for the treatment of cancer, fibroids, uterine (myoma), hormone replacement therapy, menopause, obesity, osteoporosis and atrophic vulvovaginitis.
Vasoactive intestinal polypeptide receptor 1 (VIPR1) has been shown to have contradicting effects in different cancers. Researchers have investigated the association of VIPR1 with immune inhibitory components to understand its immune landscape.
Researchers from Immatics Biotechnologies GmbH have developed bispecific T-cell engaging receptor (TCER) molecules consisting of an affinity maturated TCR, a humanized T cell-recruiting antibody and an Fc-part conferring half-life extension and favorable stability characteristics.
Arginases play key roles in metabolic pathways. Arginase 1 (ARG1) is expressed by myeloid cells in the tumor microenvironment and suppresses the functioning of T and NK cells.
Using a two-drug combination, researchers at the University of California at San Francisco (UCSF) have been able to achieve brain-specific inhibition of several kinases.
Seoul National University has patented chaperone protein DnaK (HSP70) inhibitors acting as antineoplastic enhancing agents reported to be useful for the treatment of cancer.
A new study has unveiled the signaling cascade involved in the progression of brain metastasis from breast cancer. A family of connexins participates in the process that regulate the expression of laminins that favor metastatic cells to colonize the brain.
RSS
